DGS Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$585K Buy
1,310
+149
+13% +$69.5K 0.1% 205
2025
Q4
$526K Buy
1,161
+307
+36% +$132K 0.09% 199
2025
Q3
$334K Buy
854
+350
+69% +$146K 0.06% 260
2025
Q2
$224K Buy
+504
New +$232K 0.05% 292
2024
Q4
Sell
-554
Closed -$258K 331
2024
Q3
$258K Sell
554
-131
-19% -$62.9K 0.07% 239
2024
Q2
$321K Buy
685
+22
+3% +$9.55K 0.09% 204
2024
Q1
$277K Buy
+663
New +$280K 0.08% 218

Other funds holding VRTX

DGS Capital Management's VRTX Position: Q1 2026 in Review

DGS Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 13% in Q1 2026, buying an estimated $69.5K and bringing the position to 1,310 shares worth $585K. The position accounts for 0.1% of the portfolio, ranked #205.

DGS Capital Management first reported a position in VRTX in Q1 2024 and has held it in 7 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • DGS Capital Management held 1,310 shares of Vertex Pharmaceuticals worth $585K as of Q1 2026.
  • DGS Capital Management bought 149 Vertex Pharmaceuticals shares in Q1 2026, an estimated $69.5K.
  • Vertex Pharmaceuticals made up 0.1% of DGS Capital Management's portfolio in Q1 2026, its #205 holding.
  • DGS Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 7 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on DGS Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.